Please assess the completion status of the following clinical trial:

Trial Title: Pycnogenol and Endothelial Function in Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)~* Stable cardiovascular medication for at least 1 month~* Age ≥ 18 years of age at time of signing the informed consent~* Informed consent for participation in the study~Exclusion Criteria:~* Myocardial infarction, unstable angina, stroke (within 3 months before randomization)~* Thoracic or cardiac surgery and/or coronary intervention/revascularisation procedure (within 3 months before randomization)~* Uncontrolled symptomatic congestive heart failure (NHYA\> II) in the last 4 weeks prior to study~* Renal insufficiency (Creatinine Clearance \< 50ml/min)~* Ventricular tachyarrhythmias~* Poorly controlled hypertension, defined as resting blood pressure ≥ 160/100 mmHg~* Symptomatic hypotension~* Obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism and adrenal insufficiency~* Severe uncorrected valvular disease or left ventricular outflow obstruction, which, in the opinion of the investigator, requires surgery~* Long acting nitrates~* Oral or intravenous steroids therapy~* Insulin - dependent diabetes mellitus~* Recipient of any major organ transplant (eg, lung, liver, heart) or renal replacement therapy~* Malignancy (unless healed or remission \> 5 years)~* Anaemia (Hb\< 10g/dl)~* Known to be human immunodeficiency virus (HIV) positive or active virus - hepatitis~* Alanine transaminase (ALT) or aspartate transaminase (AST) \> 3 times the upper limit of the normal range~* Known hypersensitivity to Pycnogenol®~* Alcohol, nicotine abuse or illicit drug abuse~* Pregnancy or breast-feeding, women with child - bearing potential without adequate contraception~* Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)~* Participation in another study within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pycnogenol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).